Get the Stockscreener App
15.88
3.47%
-0.57
After Hours:
15.88
Hims Hers Health Inc stock is traded at $15.88, with a volume of 18.93M.
It is down -3.47% in the last 24 hours and down -32.37% over the past month.
Hims & Hers Health Inc operates telehealth platforms, providing access to treatments for various chronic conditions, including those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. The company connects patients to licensed healthcare professionals who can prescribe medications, with prescriptions fulfilled online through licensed pharmacies. In addition, it offers access to various non-prescription health and wellness products. Through the Hims & Hers mobile applications, the company also offers access to educational programs, wellness content, community support, and other services that promote lifelong health and wellness. Geographically, it derives maximum revenue from the USA.
See More
Previous Close:
$16.45
Open:
$16.53
24h Volume:
18.93M
Relative Volume:
0.85
Market Cap:
$3.62B
Revenue:
$1.78B
Net Income/Loss:
$164.40M
P/E Ratio:
23.01
EPS:
0.69
Net Cash Flow:
$236.51M
1W Performance:
+1.79%
1M Performance:
-32.37%
6M Performance:
-67.20%
1Y Performance:
-61.16%
1-Day Range:
$15.59
$16.84
1-Week Range:
$14.31
$16.91
52-Week Range:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
15.88 | 3.75B | 1.78B | 164.40M | 236.51M | 0.69 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.76 | 57.56B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
122.23 | 53.17B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.33 | 46.62B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.75 | 38.33B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
485.06 | 21.48B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Initiated | Evercore ISI | In-line |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-21-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-23-25 | Downgrade | Needham | Buy → Hold |
| Jun-04-25 | Reiterated | Needham | Buy |
| Apr-29-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-25 | Downgrade | Citigroup | Neutral → Sell |
| Jan-07-25 | Initiated | BTIG Research | Buy |
| Dec-17-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-22-24 | Initiated | Needham | Buy |
| Aug-09-24 | Downgrade | Imperial Capital | Outperform → In-line |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Apr-16-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-10-24 | Initiated | Canaccord Genuity | Buy |
| Feb-28-24 | Upgrade | Imperial Capital | In-line → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | Imperial Capital | In-line |
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
Barclays Lowers its Price Target on Hims & Hers Health, Inc. (HIMS) to $25 and Keeps an Overweight Rating - Insider Monkey
JPMorgan Chase Reduces Stake in Hims & Hers Health to 1.7% - marketscreener.com
Hims and Hers Expands Its Technology Driven Consumer Health Platform - Zacks Investment Research
Hims & Hers Health (HIMS) Leads as Most Shorted Stock Among Mid-to-Large Caps - GuruFocus
Hims & Hers Finds A GLP-1 Hedge? HIMS Stock Rallies As RFK Jr. Signals Peptide Clearances - Stocktwits
Locally-owned pharmacy stops stocking GLP-1 medications, calls out insurance practices - AOL.com
Hims & Hers Snaps EPS Losing Streak but Shares Still in Free Fall - AOL.com
Hims & Hers Health Hits Major Milestones With Strategic Expansion - timothysykes.com
Hims Hers Health 59% Revenue Growth Meets Margin Pressure From Global Expansion - Smartkarma
Hims & Hers Slips as FDA Targets GLP-1 Compounders - GuruFocus
Hims & Hers Health stock: Technical indicators reflect volatility as price gains 4.14% - Traders Union
The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes - FinancialContent
Hims & Hers Health (HIMS) Faces High Short Interest Amid Sector Trends - GuruFocus
CI Investments Inc. Has $11.71 Million Position in Hims & Hers Health, Inc. $HIMS - MarketBeat
Canaccord Lowers Hims & Hers Health, Inc. (HIMS) Price Target Patent Amid Dispute and FDA Scrutiny - Insider Monkey
Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last - Stocktwits
Hims & Hers (HIMS) Faces Setback as FDA Issues Warning Letters - GuruFocus
Hims & Hers down as FDA targets GLP-1 compounders (HIMS:NYSE) - Seeking Alpha
US FDA warns 30 telehealth firms over misleading ads for compounded weight‑loss drugs - Reuters
Hims & Hers Health's Options Frenzy: What You Need to Know - Benzinga
Hims & Hers Health: Leaving GLP-1s Behind (NYSE:HIMS) - Seeking Alpha
HIMS Pharmacy Partner to Relaunch Compounded Version of Wegovy - GuruFocus
Strive Pharmacy says it will not resume compounded oral semaglutide sales - Reuters
Hims & Hers Health stock price forecast: Bearish momentum persists as HIMS slides 5.34% - Traders Union
Can Hims & Hers Overcome the FDA’s GLP-1 Crackdown? - TipRanks
Hims expansion may not come in time for risky GLP-1 business - Reuters
Hims & Hers Stock (+13%) : MS Conf Reassurance Sparks Short Squeeze - Trefis
United StatesK&L Gates Advises Blackbird Ventures on Eucalyptus Sale to Hims & Hers Health, Inc. - Mondaq
Insider Sell: Soleil Boughton Sells Shares of Hims & Hers Health Inc (HIMS) - GuruFocus
HIMS: Personalized care, tech-driven growth, and global expansion fuel strong revenue and margin outlook - TradingView
Hims & Hers Health (NYSE:HIMS) Stock Price Up 10.5%Should You Buy? - MarketBeat
Hims & Hers Surges on Strong Results and Strategic Acquisitions - StocksToTrade
Why Hims & Hers Health (HIMS) Is Down 6.4% After New Shelf Filing And Regulatory Scrutiny - Yahoo Finance
What's Behind The Jump In Hims & Hers Health Stock? - Benzinga
Glancy Prongay Wolke & Rotter LLP Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors - The AI Journal
Check Out What Whales Are Doing With HIMS - Benzinga
Hims & Hers stock rises 3.93% as technical indicators show strong selling pressure - Traders Union
What is behind Hims & Hers Health recent gain in value today - Traders Union
Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore - AOL.com
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know - Finviz
Hims & Hers Expands Digital Health and Global Platform Strategy - Nasdaq
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know - Yahoo Finance
Hims Faces GLP-1 Scrutiny While Broader Telehealth Growth Story Evolving - Yahoo Finance
Zacks Research Upgrades Hims & Hers Health (NYSE:HIMS) to "Hold" - MarketBeat
Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back? - Nasdaq
Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making - Nasdaq
HIMS Stock Price, Quote & Chart | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
How Investors Are Reacting To Hims & Hers Health (HIMS) Softer GLP-1 Outlook And ESOP Share Offering - simplywall.st
Inside the Legal Battle Between Novo Nordisk and Hims & Hers - The Fashion Law
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026 - FinancialContent
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):